Cargando…

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haupt, Robert, Baracco, Lauren, Harberts, Erin M., Loganathan, Madhumathi, Kerstetter, Lucas J., Krammer, Florian, Coughlan, Lynda, Ernst, Robert K., Frieman, Matthew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838488/ https://www.ncbi.nlm.nih.gov/pubmed/36639569 http://dx.doi.org/10.1038/s41598-023-27965-x

Ejemplares similares

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
por: Lu, Ti, et al.
Publicado: (2023)

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
por: Gregg, Kelsey A., et al.
Publicado: (2017)

Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
por: Kerstetter, Lucas J., et al.
Publicado: (2021)

Biogeography and environmental preferences of Butia yatay (Mart.) Becc
por: Silva, G. Carolina, et al.
Publicado: (2023)

TLR Signaling and DNA Repair: Are They Associated?
por: Harberts, Erin, et al.
Publicado: (2012)

Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice
por: Puente-Massaguer, Eduard, et al.
Publicado: (2023)

Defining Targets for Adsorbent Material Performance to Enable Viable BECCS Processes
por: Holmes, Hannah E., et al.
Publicado: (2021)

Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
por: Lee, Katherine S, et al.
Publicado: (2023)

Effect of Massoia (Massoia aromatica Becc.) Bark on the Phagocytic Activity of Wistar Rat Macrophages
por: Hertiani, Triana, et al.
Publicado: (2018)

Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses
por: Puente-Massaguer, Eduard, et al.
Publicado: (2023)

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
por: Jangra, Sonia, et al.
Publicado: (2022)

Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination
por: Karlsson, Erik A., et al.
Publicado: (2016)

Utilization of zygotic embryos of an economic rattan palm Calamus thwaitesii Becc. (Arecaceae) for somaplant regeneration and cryobanking
por: Hemanthakumar, A. S., et al.
Publicado: (2012)

Two new records of palm species for Gabon: Sclerosperma profizianum Valk. & Sunder. and Eremospatha quiquecostulata Becc.
por: Bourobou Bourobou, Paul Henri, et al.
Publicado: (2016)

The Garlic Tree of Borneo, Scorodocarpus borneensis (Baill.) Becc. (Olacaceae): Potential Utilization in Pharmaceutical, Nutraceutical, and Functional Cosmetic Industries
por: Wiart, Christophe, et al.
Publicado: (2023)

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
por: Pardi, Norbert, et al.
Publicado: (2022)

A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
por: Strohmeier, Shirin, et al.
Publicado: (2022)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Role of TLR5 and Flagella in Bacillus Intraocular Infection
por: Parkunan, Salai Madhumathi, et al.
Publicado: (2014)

Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies
por: Goff, Peter H., et al.
Publicado: (2013)

Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges
por: Coughlan, Lynda, et al.
Publicado: (2015)

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
por: Jangra, Sonia, et al.
Publicado: (2020)

Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice
por: Wohlbold, Teddy John, et al.
Publicado: (2015)

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice
por: Nachbagauer, Raffael, et al.
Publicado: (2016)

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
por: Madsen, Anders, et al.
Publicado: (2019)

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
por: Bliss, Carly M., et al.
Publicado: (2022)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Synergistic TLR2/6 and TLR9 Activation Protects Mice against Lethal Influenza Pneumonia
por: Tuvim, Michael J., et al.
Publicado: (2012)

Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice
por: Miller, Shannon M., et al.
Publicado: (2020)

A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic
por: Lau, Yuk-Fai, et al.
Publicado: (2009)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
por: Amanat, Fatima, et al.
Publicado: (2021)

Stockpiling Supplies for the Next Influenza Pandemic
por: Radonovich, Lewis J., et al.
Publicado: (2009)

MPL Adjuvant Contains Competitive Antagonists of Human TLR4
por: Wang, Yi-Qi, et al.
Publicado: (2020)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

The Protective Role of TLR3 and TLR9 Ligands in Human Pharyngeal Epithelial Cells Infected with Influenza A Virus
por: Han, Yan, et al.
Publicado: (2014)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
por: Logue, James, et al.
Publicado: (2023)

Adjuvanted influenza vaccine dynamics
por: Parra-Rojas, César, et al.
Publicado: (2019)

Advances in Adjuvanted Influenza Vaccines
por: Shichinohe, Shintaro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qvkoisup07qkev4ifju4djp8ee